Navigation Links
Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia
Date:9/9/2013

SAN DIEGO, Sept. 9, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the 50mg dose of NBI-98854, a small molecule VMAT2 inhibitor in development for tardive dyskinesia, did not meet the primary endpoint in the Phase IIb Kinect study while the 100mg dose showed a statistical and clinically significant improvement. The pre-specified primary endpoint was the change-from-baseline in the Abnormal Involuntary Movement Scale (AIMS) at Week 6 in the intent-to-treat (ITT) population.

Although the 50mg dose of NBI-98854 did not reach statistical significance for the primary endpoint at Week 6, the 100mg dose, utilizing the blinded central video AIMS assessment, showed a statistically significant and clinically meaningful reduction in tardive dyskinesia symptoms at Week 2 (the end of the 100mg dose interval). AIMS scores were reduced by 5.5 points in the 100mg per-protocol (PP) group compared to a reduction of 2.7 points in placebo (p=0.008), and the responder rate (>= 50% improvement from baseline) was 48% in the 100mg group compared to 23% in placebo (p=0.034). The 100mg dose was expected to be a maximum tolerated dose based on earlier data; however in this patient population, 100mg was well tolerated. The pre-specified statistical analysis plan included three data sets: safety set (all subjects with at least one dose), ITT set (all randomized subjects with at least one AIMS assessment) and the PP set (all subjects except those with no detectable drug levels at the evaluation time point).

"Although this was not the result we anticipated in the 50mg dose based on the data set from the earlier clinical studies, we were pleased to see a clear dose related response at the end of Week 2, with the 100mg dose, " said Kevin C. Gorman, President and Chief Executive Officer of Neuroc
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
2. Neurocrine Biosciences Reports First Quarter 2012 Results
3. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
4. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2012 Financial Results
5. Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2012 Financial Results
7. Neurocrine Biosciences To Present At Lazard Capitalmarkets 9th Annual Healthcare Conference
8. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
9. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
10. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
11. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014  Aptuit LLC announces that Aptuit SSCI, ... , has enhanced its capabilities in the areas ... large molecules, including biologic drugs, metabolites, and polymers, ... mass spectrometer. In making the announcement, ... "The expanded large molecule capability enhances our early ...
(Date:8/21/2014)... Aug. 21, 2014  Vermillion, Inc. (NASDAQ: ... cancers and women,s health, has appointed Holly B. ... Markets. Ms. Bauzon has a proven track ... coverage for laboratory services companies. She has more than ... Inc., where she held the position of Director, Lab ...
(Date:8/21/2014)... 21, 2014  eRelevance Corporation ( www.erelevancecorp.com ), ... that it has completed integration with Nextech, a ... Surgery and Dermatology practices. "Integration allows ... healthcare practices using Nextech," stated Bob Fabbio ... information from the EMR we are able to ...
Breaking Medicine Technology:Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses 2Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2eRelevance Corporation Integrates with Nextech Electronic Medical Records 2
... , FORT COLLINS, Colo., Dec. 14 Manchester Pharmaceuticals, ... (chenodiol tablets). On October 22, 2009, the US ... therapy for patients suffering from gallstones in whom surgery ... advanced age. , Chenodal prescriptions have started to be ...
... 14 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) today ... the addition of Lt. Gen. Ronald R. Blanck, DO, U.S. ... Associates, a federal health services consulting firm based in Falls ... nine members. , Dr. Blanck began his military career in ...
Cached Medicine Technology:Manchester Announces Availability of Chenodal(TM) 2Oxygen Biotherapeutics, Inc. Expands Board of Directors 2
(Date:8/23/2014)... 23, 2014 A team of New York ... longer when preceded by surgery and delivered by an experienced ... new study. Click here to read it now . ... cases of mesothelioma patients who underwent hemithoracic (one ... dose to the shape of a tumor. Patients who ...
(Date:8/23/2014)... Board of Directors voted on Monday, August 18th to approve ... for commercial and industrial properties. This was accomplished with ... in Carmel, California. , This is a historical moment, ... the State of California has approved this technology for use ... can now be used as a sole source of water ...
(Date:8/23/2014)... TX (PRWEB) August 23, 2014 Youth ... of Texas. It’s no different in Houston, TX. Substance ... are falling victim to drug and alcohol dependency in ... are looking to beat substance abuse, but don’t know ... juvenile treatment facility can be a challenge because most ...
(Date:8/22/2014)... 23, 2014 The IT manager of ... hosting for several years. He has recently announced that ... hosting suppliers in 2014. , GoDaddy is a popular ... features and great hosting solutions at affordable rates. It ... for shared hosting plans depend on the length of ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 AWeber, ... services that currently helps more than 120,000 small ... caught the attention of Shane Michaels, prompting an investigative ... crucial element for any online marketing campaign, despite what ... in the marketing world,” reports Michaels. “AWeber is a ...
Breaking Medicine News(10 mins):Health News:New Study Links Hospital Experience and Prior Surgery with Mesothelioma Radiation Success, According to Surviving Mesothelioma 2Health News:Historical Moment in the Monterey Peninsula, Brings Drought Relief Solution to California, with the Help of EcoloBlue and AWG Technology 2Health News:New Houston Hotline Assisting Juveniles in Locating Dependable Rehabilitation Help 2Health News:AWeber: Review Exposes Affordable Provider of Opt-In Email Marketing Services 2
... Mass., Nov. 25 Gene Network Sciences, Inc.,(GNS) ... company, Fina,Technologies, Inc. (Fina) to leverage its proprietary ... new arena -- that of,quantitative financial trading and ... raw clinical and genomics data to identify drug,targets, ...
... Season , , ROSELAND, N.J., ... during the busy holiday season. Unfortunately many get drawn into buying ... At airports, it,s easy to wind up eating unhealthy foods ... a rush or have time to spend before a flight, you ...
... Pharmaceuticals, Inc.,(Nasdaq: ARNA ) announced today that the ... Health Care Conference on December 3, 2008 at 2:30,p.m. Eastern ... Hotel in,New York City. Jack Lief, Arena,s President and Chief ... including its clinical,development and discovery programs. , ...
... /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: NRI), a Canadian ... of drug products delivered to and through the skin, ... and development subsidiary, has signed a research and development ... develops and markets skin care products. Financial details of ...
... 25 Hillenbrand, Inc.,(NYSE: HI ) -- ... United States,District Court in the Southern District of Texas ... denied in,two previously disclosed antitrust lawsuits against Batesville Casket ... As previously reported, a purported consumer ...
... WELLINGTON, Fla., Nov. 25 The Quantum Group,Inc. ... solutions provider for,the healthcare industry, announced today that ... approval and a Certificate,of Authority from the State ... RASI has been established to provide administrative ...
Cached Medicine News:Health News:Gene Network Sciences Announces Creation of Spin-off Entity Focused on Quantitative Finance and E-Commerce 2Health News:Gene Network Sciences Announces Creation of Spin-off Entity Focused on Quantitative Finance and E-Commerce 3Health News:Nutritionist Claudia Gonzalez Shares Tips for Eating Well On-the-Go During the Busy Holiday Rush 2Health News:Arena Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference 2Health News:Arena Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference 3Health News:Nuvo Research subsidiary signs collaboration agreement with Fortune Global 500 company 2Health News:Nuvo Research subsidiary signs collaboration agreement with Fortune Global 500 company 3Health News:Magistrate Judge Recommends Denial of Class Certification in Funeral Industry Antitrust Litigation 2Health News:The Quantum Group Announces State Approval of TPA Application for Subsidiary Company Renaissance Administrative Solutions, Inc. 2Health News:The Quantum Group Announces State Approval of TPA Application for Subsidiary Company Renaissance Administrative Solutions, Inc. 3Health News:The Quantum Group Announces State Approval of TPA Application for Subsidiary Company Renaissance Administrative Solutions, Inc. 4
Katena ophthalmic burr for polishing pterygiums, includes one round diamond burr and has an storage case....
Illuminated Trial Lens Set is an attractive set of trial lenses worked to a high standard of accuracy....
Trial Lens Sets....
... is the first ... to offer two kinds ... and taurine. Cleans, rinses, ... and conditions any soft ...
Medicine Products: